Signia, a leading global brand in hearing care, continues to innovate and offer an extensive range of hearing aids that cater to diverse needs and preferences. As of 2025, Signia’s portfolio features four major technology platforms and various form factors, seamlessly blending advanced sound processing, connectivity, and style to enhance listening experiences for people with hearing loss.
Signia’s Hearing Aid Platforms
1. Integrated Xperience (IX)
Introduced in 2023, the IX platform is Signia’s most advanced line, designed to transform how wearers hear conversations in real-world noisy settings. Utilizing two separate processors, the IX technology independently manages speech and background sounds, delivering crystal-clear audio with natural sound and reduced listening effort. The Pure Charge&Go BCT IX models are flagship representatives, offering:
-
Up to 48 processing channels.
-
Extended battery life up to 37 hours.
-
Bluetooth Classic connectivity for seamless streaming.
-
RealTime Conversation Enhancement for dynamic conversational clarity.
Popular IX models include Pure Charge&Go 7IX, Styletto 7IX, and Silk 7IX, with prices ranging approximately from ₹79,990 to ₹7,99,990 for kits.
2. Augmented Xperience (AX)
Launched in 2019, AX platform hearing aids emphasize sound processing that dynamically distinguishes focused speech from ambient noise, reducing listening strain. They provide high-resolution hearing with multiple channels and convenient wireless features.
-
Models like Styletto 7AX, Pure C&G 7AX, and Insio Charge&Go 7AX.
-
Bluetooth streaming via ASHA or MFi.
-
Rechargeable versions as well as classic battery types.
-
Price ranges from ₹1,24,990 to ₹7,45,990 per device.
3. Xperience (X)
The X platform is aimed at users who need dependable hearing enhancement with adaptive sound control and Bluetooth connectivity. It is well-suited for everyday use in various environments and at competitive prices.
-
Models include Motion C&G 7X and Pure 312 7AX.
-
Offers rechargeable options and wireless streaming.
-
Price range around ₹30,990 to ₹6,50,990.
4. Primax (px)
Primax caters to budget-conscious users needing reliable amplification without advanced wireless or processing technologies.
-
Available in multiple form factors, including ITE and BTE.
-
Prices from ₹10,990 to ₹31,990.
-
Focus on essential hearing aid functionalities for straightforward hearing improvement.
Product Performance Classes
Signia classifies its hearing aids across performance levels for tailored user experiences:
-
Premium Class (Level 7): Top-tier models with best-in-class speech clarity and features.
-
Advanced Class (Level 5): Balanced high performance and affordability.
-
Standard Class (Level 3): Reliable everyday use hearing aids with core features.
-
Essential Class (Levels 1 & 2): Simple, user-friendly models for mild hearing loss or first-time users.
-
Basic Class: Entry-level devices offering fundamental hearing support at low cost.
Unique Features Across the Range
-
RealTime Conversation Enhancement (RTCE): Tracks ongoing speech dynamics for prioritized focus on speakers.
-
Own Voice Processing (OVP™): Ensures wearer’s voice sounds natural without awkward amplification.
-
Bluetooth Connectivity: Direct streaming from iOS, Android, and other Bluetooth devices for music, calls, and TV.
-
Rechargeability: Most models offer long-lasting rechargeable batteries including portable charging cases.
-
Remote Care: Wireless remote fitting and adjustments via Signia app.
-
Durability: IP68 dust and water resistance rating on premium models.
Conclusion
Signia’s 2025 hearing aids combine breakthrough sound science with user-centric designs ranging from discreet invisible models to stylish rechargeable RICs and robust BTEs for all types of hearing loss. Whether seeking premium performance or simple amplification solutions, Signia’s diverse lineup delivers enhanced hearing comfort, connectivity, and convenience to help users enjoy conversations and daily living brilliantly.
For personalized hearing aid selection and fittings, professional audiologist evaluation and trial remain recommended.